TD Cowen keeps USD 980.00 target for Regeneron stock

Published on 10/27/2026 at 16:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

TD Cowen kept its Buy rating and USD 980.00 target on October 21, 2026. Regeneron stock costs EUR 730.25 on October 27, 2026 at 4:37 p.m. CEST.

TD Cowen keeps USD 980.00 target

TD Cowen maintained its Buy rating and USD 980.00 target on October 21, 2026.
Regeneron reported USD 4.29 billion in second-quarter revenue, up 16.73 percent year over year.
Regeneron stock costs EUR 730.25 at Lang & Schwarz on October 27, 2026 at 4:37 p.m. CEST.
Regeneron is scheduled to report third-quarter results on October 30, 2026.

Regeneron, US75886F1075, Illustration mit AI erstellt.

Regeneron Pharmaceuticals stock (ISIN US75886F1075) has a USD 980.00 price target from TD Cowen, which maintained its Buy rating on October 21, 2026, according to Markets Insider. Regeneron stock was trading at EUR 730.25 at Lang & Schwarz on October 27, 2026 at 4:37 p.m. CEST.

Second-quarter revenue reached USD 4.29 billion

Regeneron reported USD 4.29 billion in second-quarter revenue, up 16.73 percent from USD 3.68 billion in the same period a year earlier. The company also reported net income of USD 1.30 billion for the quarter, compared with USD 1.39 billion a year earlier, according to Yahoo Finance.

Stock stays below its yearly high

The Nasdaq-listed stock was at USD 814.07 on October 27, 2026 at 11:44 a.m. EDT. Its USD 83.8 billion market capitalization placed the company below its USD 859.34 52-week high and above its USD 591.52 low. The trailing price-to-earnings ratio was 20.14.

What comes before the next report?

Regeneron is scheduled to report third-quarter results on October 30, 2026, according to Yahoo Finance. The upcoming report will provide the next periodized comparison for revenue and earnings.

How Regeneron compares with peers

Vertex Pharmaceuticals was trading at USD 515.21 on October 27, 2026 at 11:44 a.m. EDT, with a 30.01 trailing price-to-earnings ratio and USD 130.6 billion market capitalization. Gilead Sciences stood at USD 157.12 at the same time, with a negative trailing price-to-earnings ratio and USD 194.8 billion market capitalization. Both companies operate in biotechnology, while Regeneron combines antibody research with marketed medicines.

Analyst target remains the key marker

TD Cowen's USD 980.00 target sits above the USD 814.07 Nasdaq price, while the current euro quotation provides the Germany-facing trading view. The target, second-quarter revenue comparison and October 30 reporting date give investors three separate markers for assessing the next update. The stock was trading at EUR 730.25 at Lang & Schwarz on October 27, 2026 at 4:37 p.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Regeneron stock.